Genedata Biologics at Eighth Annual PEGSGeneData USA

News

Genedata Biologics at Eighth Annual PEGS
03 May 2012

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata BiologicsTM will be a featured technology at the Eighth Annual PEGS.

A first-in-class, end-to-end solution for biologics R&D, Genedata Biologics will be showcased in a Bayer HealthCare Pharmaceuticals presentation at the PEGS Engineering Antibodies session. The presentation will detail the implementation of an automated high-throughput biologics screening process for the discovery and optimization of monoclonal antibody leads. Examples of laboratory workflows and data management using the Genedata Biologics software platform will be presented. Genedata Biologics will also be featured in poster sessions at PEGS, the foremost protein engineering summit (Boston Park Plaza Hotel & Towers; April 30 - May 4).

Development of biopharmaceuticals is fundamentally different from classical small molecule drug development. Biologics R&D requires highly specialized, complex, time-consuming, and costly processes, based on sophisticated workflows and novel discovery technologies. Genedata Biologics is a dedicated data management solution tailored to address the specific requirements of the biologics R&D process. Simplifying and streamlining laborious, manual processes such as cloning or instrument operation, the Genedata Biologics platform increases efficiency and throughput. Improved quality of results through the reduction of ad-hoc and error-prone sample and data handling is also realized.

PEGS presentation and poster sessions will examine how Genedata Biologics enables more flexible and ultra high-throughput workflows, and how classic process bottlenecks can be removed. Concrete use cases will include:
• HT antibody phage-display;
• screening automation;
• affinity maturation;
• design and evaluation of engineered molecules;
• high-throughput expression, purification, and analytics of novel biologics candidates.
"Genedata Biologics, already adopted by more than 25% of world's leading pharmas and biotechs, is the result of a five-year development program in close collaboration with leading international players in biologics R&D," noted Dr. Othmar Pfannes, CEO of Genedata. "Through collaboration with leading companies such as Bayer HealthCare, we've developed the first, dedicated data management platform for biologics R&D. We are honored to share our findings and software solution with our colleagues at PEGS."

Request Info

Company website